Liu 2012.
Study characteristics | |||
Patient sampling | Study design: prospective cohort study. Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing. Inclusion criteria: women who planned an invasive testing for 1 or more of the following reasons: abnormality in plasma test, older than 35 years old, infant deformity (ultrasound), taken drugs (teratogen) during early pregnancy or history of malformation caused by virus infection, history of birth defect caused by abnormal chromosome, history of fetus stopping growth or repeated spontaneous abortion or dead fetus or dead birth for unknown reason, history of chromosome abnormality in family or either of the couple, too much or little amniotic fluid. Exclusion criteria: not reported. | ||
Patient characteristics and setting | Number enrolled: 153 pregnant women.
Number available for 2 x 2 table: 153 pregnant women (whole cohort included in analyses). Setting: Henan Province People Hospital Medical. Recruitment period: October to November 2011. Ethnicity: Asian. Gestational age: more than 14 weeks. Mean maternal age (± SD; range): 32.3 (± 1.2; 20 to 44) years. Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement) or biochemical screening or both. Language of the study: Chinese. |
||
Index tests | gNIPT by MPSS on Illumina HiSeq sequencer in multiplex. Fetal fraction DNA: not reported. Blood samples for gNIPT were collected 30 minutes before reference standard. Cutpoint: positive if Z score ≥ 3. It is not reported if gNIPT was a commercial or an in‐house test. |
||
Target condition and reference standard(s) | Target conditions: T21, T18, T13, 45,X and 47,XYY. 47,XXY and 47,XXX were also assess but no case were found. Reference standard: fetal karyotype of amniotic fluid. | ||
Flow and timing | Blood samples for gNIPT were obtained 30 minutes prior to the invasive procedure (reference standard).
gNIPT was a second‐tier test. No failed sample reported. No repeated test reported. |
||
Comparative | |||
Aim to study | To determine the feasibility and accuracy of detecting numerical chromosomal abnormalities by high‐flux sequencing analysis of ccfDNA from maternal plasma. | ||
Funding source or sponsor of the study | Study funded by by the Nalional Natural Science Foundation of China and a Medical Science and Technology Research Project of Henan Province. | ||
Informations about the authors contacted | Author was contacted on 11 April 2016 but contact author's email is no longer valid. | ||
Notes | |||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | No | ||
Was a case‐control design avoided? | Yes | ||
Did the study avoid inappropriate exclusions? | Unclear | ||
Unclear | Low | ||
DOMAIN 2: Index Test MPSS | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | Yes | ||
If a threshold was used, was it pre‐specified? | Yes | ||
Low | Low | ||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | Yes | ||
Low | Low | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Yes | ||
Did all analysed patients receive the reference standard? | Yes | ||
Were all patients included in the analysis? | Yes | ||
Low |